EyePoint, Inc.: approves prioritization and plans 53% workforce reduction

What happened On Oct 17, 2026, EyePoint, Inc. reported that its board of directors approved a strategic prioritization plan to reduce operating expenses and focus resources on its late-stage DURAVYU™ program in diabetic macular edema (DME). On Oct 19, 2026, the company issued a press release announcing the Prioritization and, among other things, its estimated cash, cash equivalents and short-term investments as of Sep 30, 2026. The press release noted those amounts are preliminary, have not been reviewed by the company’s independent registered public accounting firm and are subject to change.

Key details

• The Prioritization includes concluding the pivotal Phase 3 wet age-related macular degeneration (wet AMD) clinical trials early and prioritizing the company’s pivotal Phase 3 DME trials (COMO and CAPRI).
• The company plans to reduce its workforce by approximately 53%, with the substantial majority of the workforce reduction expected to occur during the fourth quarter of 2026 and to be completed during the first half of 2027.
• EyePoint estimates aggregate charges of approximately $9,000,000 related to employee separation benefits (employee severance and related expenses); a majority of these charges are expected to be recognized during the fourth quarter of 2026, with remaining charges recognized through the third quarter of 2027.
• The company expects that substantially all of these charges will result in cash expenditures over the same time period; estimates and timing are subject to change as the Prioritization is implemented.

Why it may matter

• Item 2.05 (costs associated with exit or disposal activities) was reported and covers the estimated employee separation charges and related timing.
• Item 2.02 (results of operations and financial condition) was reported and covers the company’s preliminary estimated cash, cash equivalents and short-term investments as of Sep 30, 2026; those amounts are unaudited and subject to change.
  This filing does not show why the insider traded or why the company acted.